Ossiam Has $2.96 Million Holdings in PerkinElmer, Inc. (NYSE:PKI)

Ossiam grew its holdings in PerkinElmer, Inc. (NYSE:PKI) by 126.6% during the second quarter, Holdings Channel.com reports. The firm owned 16,264 shares of the medical research company’s stock after acquiring an additional 9,087 shares during the quarter. Ossiam’s holdings in PerkinElmer were worth $2,964,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of PKI. Price T Rowe Associates Inc. MD increased its holdings in PerkinElmer by 60.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,312,457 shares of the medical research company’s stock worth $681,535,000 after buying an additional 1,992,799 shares during the last quarter. Ceredex Value Advisors LLC boosted its position in shares of PerkinElmer by 31.2% in the second quarter. Ceredex Value Advisors LLC now owns 1,641,949 shares of the medical research company’s stock valued at $253,533,000 after acquiring an additional 390,612 shares during the period. Renaissance Technologies LLC acquired a new position in PerkinElmer in the first quarter valued at about $41,450,000. Massachusetts Financial Services Co. MA raised its stake in PerkinElmer by 6.6% in the first quarter. Massachusetts Financial Services Co. MA now owns 4,414,201 shares of the medical research company’s stock valued at $566,298,000 after purchasing an additional 271,538 shares in the last quarter. Finally, State of Michigan Retirement System raised its stake in PerkinElmer by 894.2% in the second quarter. State of Michigan Retirement System now owns 280,070 shares of the medical research company’s stock valued at $43,246,000 after purchasing an additional 251,900 shares in the last quarter. Institutional investors own 92.84% of the company’s stock.

In related news, insider James M. Mock sold 6,080 shares of the stock in a transaction on Monday, September 20th. The stock was sold at an average price of $184.87, for a total value of $1,124,009.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.55% of the stock is owned by company insiders.

PKI has been the subject of a number of analyst reports. Royal Bank of Canada boosted their price target on PerkinElmer from $48.00 to $49.00 and gave the company an “outperform” rating in a research note on Monday, August 9th. Evercore ISI reaffirmed an “outperform” rating and issued a $170.86 price objective (down previously from $174.00) on shares of PerkinElmer in a research note on Tuesday, July 27th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $172.11 price objective (up previously from $150.00) on shares of PerkinElmer in a research note on Tuesday, July 27th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, PerkinElmer presently has a consensus rating of “Buy” and an average price target of $152.50.

Shares of PerkinElmer stock traded up $3.80 on Thursday, reaching $171.80. 1,158 shares of the company’s stock were exchanged, compared to its average volume of 855,412. The company has a market capitalization of $19.26 billion, a P/E ratio of 15.98, a price-to-earnings-growth ratio of 0.50 and a beta of 1.10. PerkinElmer, Inc. has a 52 week low of $119.94 and a 52 week high of $192.00. The firm’s 50-day moving average is $181.51 and its two-hundred day moving average is $158.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.56 and a current ratio of 2.01.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Sunday, July 25th. The medical research company reported $2.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.40 by $0.43. PerkinElmer had a return on equity of 37.29% and a net margin of 24.35%. The firm had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the business earned $1.23 EPS. On average, analysts expect that PerkinElmer, Inc. will post 9.91 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 12th. Investors of record on Friday, October 22nd will be issued a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.16%. The ex-dividend date is Thursday, October 21st. PerkinElmer’s dividend payout ratio is currently 3.37%.

PerkinElmer Profile

PerkinElmer, Inc engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments.

Further Reading: Stocks Increasing Dividends

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.